1. Home
  2. Analysis
  3. Gemfibrozil
  4. Aromasin

Gemfibrozil and Aromasin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gemfibrozil and Aromasin. Common interactions include anxiety among females.

The phase IV clinical study analyzes what interactions people who take Gemfibrozil and Aromasin have. It is created by eHealthMe based on reports of 40 people who take Gemfibrozil and Aromasin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

40 people who take Gemfibrozil and Aromasin together, and have interactions are studied.

What is Gemfibrozil?

Gemfibrozil has active ingredients of gemfibrozil. It is often used in high blood cholesterol. eHealthMe is studying from 17,437 Gemfibrozil users for its effectiveness, alternative drugs and more.

What is Aromasin?

Aromasin has active ingredients of exemestane. It is often used in breast cancer. eHealthMe is studying from 12,129 Aromasin users for its effectiveness, alternative drugs and more.

Number of Gemfibrozil and Aromasin reports submitted per year:

Gemfibrozil and Aromasin drug interactions.

Common Gemfibrozil and Aromasin drug interactions by gender *:

female:

  1. Anxiety
  2. Pain
  3. Rotator cuff syndrome
  4. Asthenia
  5. Blood creatinine increased
  6. Bone disorder
  7. Dizziness
  8. Fatigue
  9. Anhedonia
  10. Ankle fracture

male:

n/a

Common Gemfibrozil and Aromasin drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Arthropathy
  2. Back pain
  3. Biliary colic
  4. Bipolar i disorder
  5. Bone swelling
  6. Bruxism
  7. Bundle branch block left
  8. Burning sensation
  9. Cardiomyopathy
  10. Chest pain

60+:

  1. Anxiety
  2. Pain
  3. Rotator cuff syndrome
  4. Asthenia
  5. Blood creatinine increased
  6. Anhedonia
  7. Ankle fracture
  8. Dizziness
  9. Dyspnoea
  10. Metastases to liver

Common conditions people have *:

  1. Hypercalcaemia (elevated calcium (ca+) level in the blood): 15 people, 37.50%
  2. High Blood Pressure: 15 people, 37.50%
  3. Anaemia (lack of blood): 11 people, 27.50%
  4. Urticaria (rash of round, red welts on the skin that itch intensely): 5 people, 12.50%
  5. Breast Cancer Female: 3 people, 7.50%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 5.00%
  7. Bipolar Disorder (mood disorder): 2 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Gemfibrozil and Aromasin?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Gemfibrozil and Aromasin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Gemfibrozil side effects:

Browse all side effects of Gemfibrozil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Aromasin side effects:

Browse all side effects of Aromasin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Gemfibrozil interactions:

Browse all interactions between Gemfibrozil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Aromasin interactions:

Browse all interactions between Aromasin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gemfibrozil and exemestane (the active ingredients of Gemfibrozil and Aromasin, respectively), and Gemfibrozil and Aromasin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Gemfibrozil and Aromasin.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.